secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2026-07-29T15:38:46+00:00
Accession:  0001703057-26-000039
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera announces collaboration with Vertex to develop T-cell engagers; receives $281M upfront
--------------------------------------------------------------------------------

- Collaboration with Vertex (VRTX) to discover multispecific T-cell engagers for autoimmune diseases and other conditions.
- AbCellera leads discovery and early development; Vertex funds all R&D costs and holds commercialization rights.
- AbCellera receives $281 million in total upfront payments, plus preclinical, development, regulatory, and commercial milestones and tiered royalties.
- AbCellera may also perform cell line development, process development, and clinical manufacturing through Phase 1 for any program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/0001703057-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/abcl-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001703057-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer